Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system.
Results from a first-in-human clinical trial in subjects with MPS I
SEATTLE, Jan. 27, 2025 /PRNewswire/ -- Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will feature oral and poster presentations at the upcoming WORLDSymposium™ 2025, held in San Diego, February 3-7, 2025.
Immusoft will present the following:
Oral Presentation: Friday, February 7th, 9:00 AM PST, Dr. Paul Orchard, MD.
Title: Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system: Results from a first-in-human clinical trial in subjects with MPS I
Presenter: Paul J. Orchard, MD., Professor, Division of Pediatric Blood and Marrow Transplantation & Cellular Therapy University of Minnesota Medical School
Poster Presentation: Wednesday, February 5th, 2026, 3:30-5:30 PM PST, Kiosk 27-B.
Title: Safety and initial activity of autologous human B cells genetically engineered to express human iduronidase using the Sleeping Beauty transposon system: Results from a first-in-human clinical trial in subjects with MPS I
Presentation Category: Translational Research & Late-Breaking Science Posters (LB-35 to LB-62)
Immusoft is developing B cells as biofactories for therapeutic protein delivery. This new modality has the potential to be both durable and redosable. The Company’s lead drug candidate, ISP-001, is the first ever engineered B cell in a human clinical trial and a first-in-class investigational treatment for mucopolysaccharidosis type I (MPS I), a rare lysosomal storage disease. ISP-001 is an autologous B cell product engineered to express human alpha-L-iduronidase (IDUA) for the treatment of MPS I.
In this first-in-human clinical trial, the patient was dosed without the need for a preconditioning regimen (required for gene-modified stem cells) or immunosuppression (required for most systemic virus-delivered gene therapy), both of which can be associated with severe toxicities.
There is a significant unmet need for new therapies with improved efficacy and convenience in MPS I, where the current standard of care is enzyme replacement therapy (ERT) or hematopoietic stem cell transplant (HSCT). Due to their capacity for high-level protein production, their natural ability to engraft in the bone marrow without the need for toxic preconditioning, and their ability to manufacture a multitude of protein types, B cells have the potential to address unmet needs across numerous therapeutic indications.
Additional information regarding the WORLDSymposium™ presentation can be found at: https://worldsymposia.org/.
About Immusoft
Immusoft is a cell therapy company focused on developing novel approaches to treat rare diseases by sustained delivery of protein therapeutics from a patient’s own B cells. The company is developing a technology platform called Immune System Programming (ISP™), which modifies a patient’s B cells and instructs the cells to produce gene-encoded medicines. The B cells that are reprogrammed using ISP become miniature drug factories that are expected to survive in patients for many years. The company is based in Seattle, WA. For more information, visit www.immusoft.com.
Contact
Media
Susan RobertsRoberts Communications
202-779-0929
View original content to download multimedia:https://www.prnewswire.com/news-releases/immusoft-to-present-positive-data-from-the-first-engineered-b-cell-in-a-human-clinical-trial-at-the-21st-annual-worldsymposium-2025-302360779.html
SOURCE Immusoft
